- Hayward, CA
CymaBay Therapeutics is focused on the development and commercialization of proprietary new medicines for critical human diseases.
CymaBay Therapeutics is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on the development and commercialization of proprietary new medicines for important human diseases. We are committed to developing breakthrough medicines that improve the lives of patients and their families. CymaBay was seeded with the assets from an earlier metabolic disease company in which more than $120M was invested to produce a robust pipeline.
Arhalofenate is a novel oral small molecule being developed to treat the approximately 1 million gout patients that flare three or more times per year. Gout flares are painful inflammatory episodes caused by crystals of monosodium urate (MSU) that result from excess serum uric acid (sUA). In three Phase 2 studies in gout patients arhalofenate was shown to reduce the incidence and duration of flares while simultaneously lowering sUA. If confirmed in additional... See More
Current Team (3)Update
Board Members and Advisors (8)Update
Funding Rounds (5) - $100.20MUpdate
Investors UnknownOct 11, 2013 -Venture Round
Alta Partners is a leading venture capital firm in life sciences, funding over 130 companies in..
Private Equity Bank
Bay City Capital LLC (Bay City Capital) was established in 1997 for the purpose of managing..
Venture capital Firm
Venrock is a venture capital firm investing in technology and healthcare companies.
Novo A/S is a Danish private limited liability company wholly owned by the Novo Nordisk..
VantagePoint Capital Partners (formerly VantagePoint Venture Partners, until 2011) has more than..
Founded in Geneva in 1805, Pictet is today one of Switzerland's largest private banks, with..
3876 Bay Center Place
Hayward, CA 94545